Perceptive Advisors LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,888,597 shares of the biopharmaceutical company’s stock after acquiring an additional 591,925 shares during the period. Amicus Therapeutics comprises about 10.3% of Perceptive Advisors LLC’s holdings, making the stock its 2nd largest holding. Perceptive Advisors LLC owned approximately 10.76% of Amicus Therapeutics worth $269,760,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its stake in shares of Amicus Therapeutics by 3,672.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after acquiring an additional 66,209 shares during the last quarter. Alliancebernstein L.P. raised its position in Amicus Therapeutics by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock valued at $2,073,000 after purchasing an additional 28,800 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $1,057,000. Bank of Nova Scotia bought a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $1,944,000. Finally, Vanguard Group Inc. raised its position in Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after purchasing an additional 430,486 shares during the last quarter.
In other Amicus Therapeutics news, CEO John F. Crowley sold 71,735 shares of the company’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $14.75, for a total transaction of $1,058,091.25. Following the transaction, the chief executive officer now owns 380,723 shares in the company, valued at approximately $5,615,664.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John F. Crowley sold 449,295 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the transaction, the chief executive officer now owns 380,723 shares in the company, valued at approximately $5,455,760.59. The disclosure for this sale can be found here. Insiders have sold a total of 680,437 shares of company stock worth $9,734,522 in the last quarter. Company insiders own 3.40% of the company’s stock.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $13.27 on Friday. Amicus Therapeutics, Inc. has a twelve month low of $4.41 and a twelve month high of $16.60. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. During the same quarter last year, the company posted ($0.33) EPS. The firm’s revenue was up 419.0% on a year-over-year basis. equities analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.
A number of research analysts have commented on the company. Leerink Swann reaffirmed a “buy” rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, September 25th. Cowen reaffirmed a “buy” rating and set a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, August 14th. Zacks Investment Research lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Finally, BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.81.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/12/10/perceptive-advisors-llc-has-269-76-million-stake-in-amicus-therapeutics-inc-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.